MIRA INFORM REPORT

Report Date :

06.03.2013

IDENTIFICATION DETAILS

Name :	ATCO LABORATORIES LIMITED

Registered Office :	Tibet Centre, M.A. Jinnah Road, Karachi

Country :	Pakistan

Year of Establishments:	1978

Com. Reg. No.:	0006183

Legal Form :	Public Limited Company

Line of Business :	Manufacture & Marketing of Pharmaceutical Products

No. of Employees :	342

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory
Payment Behaviour :	No Complaints
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – June 30^th, 2012

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Pakistan

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

pakistan - ECONOMIC OVERVIEW

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to more than 13% for 2011, before declining to 9.3% at year-end. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in the second half of 2011, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging 2.9% per year from 2008 to 2011. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing population. Other long term challenges include expanding investment in education and healthcare, and reducing dependence on foreign donors.

Source : CIA

Business Name

ATCO LABORATORIES LIMITED

Full Address

Registered Address

Tibet Centre, M.A. Jinnah Road, Karachi, Pakistan

Tel #	92 (21) 111-111-645, 32577930, 32577931, 32577932, 32577933
Fax #	92 (21) 32563974

Short Description Of Business

a.	Nature of Business	Manufacture & Marketing of Pharmaceutical Products
b.	Year Established	1978
c.	Registration #	0006183

Factory Location

Address	B/18, S.I.T.E Karachi, Pakistan
Tel #	92 (21) 32573546, 49 (3 Lines)
Fax #	92 (21) 32563974

Auditors

M/s Jalis Ahmed & Company

(Chartered Accountants)

121, Clifton Centre, Block 5, Main Clifton, Karachi, Pakistan.

Legal Status

Subject Company was incorporated as a Private Limited Company in 1978 then afterwards it converted to Public Limited Company

Authorized Capital	Rs. 20,000,000/- divided into 200,000 shares of Rs. 100/- each
Issued & Paid up Capital	Rs. 6,300,000/- divided into 63,000 shares of Rs. 100/- each

Details of Directors

Names

Nationality

Address

Occupation

Designation

Mr. Saeed Allawala

Mr. S.M. Usman Allawala

Mr. S.M. Naseem Allawala

Mr. Aslam Usman Allawala

Mr. Salman Ilyas

Mr. Yousuf Ilyas

Pakistani

167/8, Justice Inamullah Road, K.M.C.H.S., Karachi

7/325, Haider Ali Road, D.M.C.H.S., Karachi

7-A/286, Alamgir Road, D.M.C.H.S., Karachi

7-A/328, Alamgir Road, D.M.C.H.S., Karachi

Business

Chief Executive

Director

Shareholders

Names

No. of Shares

Mr. S.M. Usman Allawala

Mr. S.M. Naseem Allawala

Mr. Aslam Usman Allawala

Mr. Saeed Allawala

Mr. Salman Ilyas

Mr. Yousuf Ilyas

Mrs. Gulzar Begum

180

21,000

10,410

10,200

600

Associates

A. Subsidiary

None

B. Associated Companies

(1) Atco Pharma International (Private) Limited, Pakistan

Products

Manufacture & marketing of different pharmaceutical class like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide, Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of AMLOD, ANFERON, ANXIT, ANZAFAX, APACE, ASCARD, ATCOCEE, ATCOL, ATCOPLEX-C, AZIDE, BETADERM, BETADERM-N, BETADERM-NM, BETAGNIC, BETASALIC, BRONKAL, BUNORFIN, CARBOPLATIN, CARDIPLANT, CARDNIT, CHEWFAM, CHLORMAX, CHOLESCOR, CHOLESTOR, CISPLATIN, CLARINASE, REPETABS, CLARITINE, CLOBEDERM, CLOBEDERM-NN, COMBINOL-D, COMBINAL JUNIOR, COMBINOL-E, CONAZ, CYTARBIN, DECAPEPTYL, DEPLUG, DEPONIT, DEPRAPRAM, DIAZOL, DIPROGENTA, DIPROSALIC, DOXORUBICIN, DOXYN, ECOZAR, ELANTAN, ELMETACIN, ELOCOM, ENACE, EULEXIN, FLUOROURACIL, FLURACIL, GELCLAIR, GEMPID, HEALIT, HIRUDOID, KETLAR, LACEROL, LEUCOVORIN, LOSTRESS, LYZAPAM, MENOGON, MERIZOLE, MEROL, MESULID, METHOTREXATE, MICRONEMA, MINIRIN, MOVELAT, MUCITAN, NAPADOC, NAVELBINE, NITROCINE, ORIMOX, PAMISOL, PANTROLOC, PENFEN, PLEXID, PROBETA, PROBETA-N, PROSTAVASIN, RUMAFEN, SCABION, SEFLOR, SILCHOL, SMECTA, SONETA, TANAKAN, TENSTATEN, TENZIL, TERBIDERM, TRANEX

Number of Employees

342

Annual Production Volume

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture

Annual Sales Volume

Year	In Pak Rupees
2011	700,000,000/- (Estimated)

Agencies

(Foreign)

(1) SCHWARZ PHARMA AG, GERMANY.

(2) MERZ PHARMACEUTICALS GMBH, GERMANY.

(3) IND-SWIFT LABORATORIES LIMITED, INDIA.

(4) ARCH PHARMA LABS LIMITED, INDIA.

(5) MAYNE PHARMA, AUSTRALIA.

(6) FERRING PHARMACEUTICALS, U.S.A.

(7) PIERRE FABRE, FRANCE.

(8) HELSINN, SWITZERLAND.

(9) SANKYO, JAPAN.

Distributors

Mainly exist at all important cities of Pakistan

Exporting Countries

Mainly to Sri Lanka, Sudan, Ethiopia, Kenya, Uganda, Yemen, Bangladesh, Myanmar, Tanzania, Uzbekistan, Kazakhstan, Afghanistan, and Turkmenistan.

Bankers

The Royal Bank of Scotland, Pakistan.

Habib Bank Limited, Pakistan.

United Bank Limited, Pakistan.

Soneri Bank Limited, Pakistan.

Askari Commercial Bank Limited, Pakistan.

Memberships

· Pakistan Pharmaceutical Manufacturers Association.

· Karachi Chamber of Commerce & Industry.

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 99.05
UK Pound	1	Rs. 153.40
Euro	1	Rs. 132.80

Comments

Subject Company was established in 1978 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is good. Trade relations are reported as fair. Company can be considered for normal business dealings at usual trade terms and conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.54.65
UK Pound	1	Rs.82.66
Euro	1	Rs.71.21

INFORMATION DETAILS

Report Prepared by :

MNL

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.